-
Bevirimat (research code MPC-4326) is an anti-HIV drug
derived from a
betulinic acid-like compound,
first isolated from
Syzygium claviflorum, a Chinese...
- has also been
extracted from
mistletoe (Phoradendron reichenbachianum).
Bevirimat, a
derivative of the
related triterpenoid betulinic acid, is
under development...
- 2014 SM 2007
Sofosbuvir 2007,
Raymond F. Schi****. N/A N/A N/A SM 2007
Bevirimat SM 2012
Ivacaftor 2012 2032 SM 2013
Vilanterol 2013 2033 SM 2014 Evolo****ab...
-
binding to gag, but
development of two
experimental drugs in this class,
bevirimat and vivecon, was
halted in 2010.
Resistance to some
protease inhibitors...
- action. C-3
esterification of
betulinic acid led to the
discovery of
bevirimat, an HIV-1
maturation inhibitor patented by Rhone-Poulenc (now Sanofi-Aventis)...
- bevacizumab-tnjn
bevacizumab gamma (INN)
bevantolol (INN)
bevasiranib (USAN, INN)
bevirimat (USAN, INN)
bevonium metilsulfate bolenol (INN)
Bexophene Bextra Bexxar...
- conducted. The
first maturation inhibitor to be
studied in
humans was
bevirimat,
another was MPC-9055 (vivecon). Both were
developed by
Myriad Genetics...
- in host CD4+ T cells.
First generation maturation inhibitors such as
bevirimat were
ineffective against some
naturally occurring changes (polymorphisms)...
-
Elvitegravir (EVG)
Raltegravir (RAL)# BI 224436† MK-2048†
Maturation inhibitors Bevirimat† BMS-955176§ Fipravirimat§
Protease Inhibitors (PI) (Discovery and development)...
- http://www.biomedcentral.com/content/pdf/1471-2105-11-37.pdf
Predicting Bevirimat resistance of HIV-1 from
genotype J.
Heaton http://www.devx...
